Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,826,230
  • Shares Outstanding, K 75,847
  • Annual Sales, $ 36,130 K
  • Annual Income, $ -215,330 K
  • EBIT $ -373 M
  • EBITDA $ -371 M
  • 60-Month Beta 1.06
  • Price/Sales 203.45
  • Price/Cash Flow N/A
  • Price/Book 8.81
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.27
  • Most Recent Earnings $-1.23 on 10/31/25
  • Next Earnings Date 02/26/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.26
  • Number of Estimates 3
  • High Estimate -1.13
  • Low Estimate -1.37
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -207.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.14 +3.28%
on 12/29/25
97.14 -7.35%
on 12/19/25
-6.14 (-6.39%)
since 11/28/25
3-Month
87.14 +3.28%
on 12/29/25
97.14 -7.35%
on 12/19/25
-3.67 (-3.92%)
since 09/29/25
52-Week
33.19 +171.17%
on 04/09/25
97.14 -7.35%
on 12/19/25
+47.93 (+113.93%)
since 12/27/24

Most Recent Stories

More News
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio ...

GMAB : 34.26 (+1.87%)
MRUS : 90.00 (-7.14%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-MRUS, ACLS, VECO, and CLCO

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

VECO : 33.11 (+4.25%)
ACLS : 93.10 (+3.58%)
MRUS : 90.00 (-7.14%)
CLCO : 9.67 (unch)
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V.  (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific...

MRUS : 90.00 (-7.14%)
HALO : 72.47 (+0.47%)
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ATXS : 12.88 (-0.77%)
MRUS : 90.00 (-7.14%)
HSII : 59.01 (+0.07%)
Halper Sadeh LLC Encourages TIPT, MRUS, PBBK Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

MRUS : 90.00 (-7.14%)
TIPT : 17.72 (-0.67%)
PBBK : 19.81 (-6.34%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - MRUS, HSII, PRO, and PBBK

NEW YORK , Nov. 4, 2025 /PRNewswire/ --

MRUS : 90.00 (-7.14%)
HSII : 59.01 (+0.07%)
PRO : 23.25 (+0.04%)
PBBK : 19.81 (-6.34%)
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Merus N.V....

GMAB : 34.26 (+1.87%)
MRUS : 90.00 (-7.14%)
Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders

NEW YORK , Oct. 21, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

MTSR : 70.50 (-0.35%)
MRUS : 90.00 (-7.14%)
VRNT : 20.51 (+1.33%)
FSFG : 32.27 (-1.22%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR, VRNT, and MRUS

NEW YORK , Oct. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

MTSR : 70.50 (-0.35%)
MRUS : 90.00 (-7.14%)
VRNT : 20.51 (+1.33%)
FSFG : 32.27 (-1.22%)
Canaccord Genuity Sticks to Its Hold Rating for Merus (MRUS)

Canaccord Genuity analyst John Newman maintained a Hold rating on Merus today and set a price target of $97.00. The company’s shares closed yesterday at $94.83.Elevate Your Investing Strategy: Take advantage...

MRUS : 90.00 (-7.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 20%. The market has entered extreme oversold territory.

See More Share

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

3rd Resistance Point 105.25
2nd Resistance Point 101.05
1st Resistance Point 95.53
Last Price 90.00
1st Support Level 85.81
2nd Support Level 81.61
3rd Support Level 76.09

See More

52-Week High 97.14
Last Price 90.00
Fibonacci 61.8% 72.71
Fibonacci 50% 65.17
Fibonacci 38.2% 57.62
52-Week Low 33.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar